ClinicalTrials.gg
Active, not recruitingNCT04464980Updated Nov 10, 2026

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

A Phase 2 interventional study of SL-BUP and XR-BUP in Opioid Use Disorder (OUD), sponsored by NYU Langone Health. Active, not recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,516
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 173 studies testing buprenorphine in Opioid-Related Disorders — 19 open to participants now, 21 under way, 5 of them phase 3. Buprenorphine · Opioid-Related Disorders.

Enrollment
2nd of 172
1,516 · median 19
Started
2021
with 4 others
Phase 2
52 of 173
1 open now
Primary completion
2026-12
later than 3 of 20 live
Registered
142nd of 173
by date
Lead sponsor
4 of 173
NYU Langone Health

Among the 173 studies testing buprenorphine in Opioid-Related Disorders, this one is the 2nd largest by enrollment of the 172 interventional ones that give a count, is one of 5 that started in 2021, is one of 52 in phase 2, reaches primary completion later than 3 of the 20 other live ones, and was the 142nd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

19 of the 173 studies testing buprenorphine in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies testing buprenorphine in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

Read the detailed description

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
  3. To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.

03

Conditions studied

  • Opioid Use Disorder (OUD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Retention Phase:

  1. 18 years of age or older;
  2. Meet criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
  3. Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
  4. If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
  5. Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
  6. In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
  7. Willing and able to provide written ;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of , willing to practice an effective method of for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Retention Phase:

  1. Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
    3. Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
  3. Known allergy or sensitivity to preferred medication or its components;
  4. Maintenance on methadone at the time of signing consent;
  5. For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;
  6. For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., >40, excess fat tissue over the buttocks, emaciation);
  7. If female, currently pregnant or breastfeeding or planning on conception;
  8. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
  9. Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;
  10. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).

Inclusion Criteria for Discontinuation Phase:

  1. 18 years of age or older;
  2. Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
  3. Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
  4. Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
  5. If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
  6. Willing to be randomized to either MM or to MMD;
  7. Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Discontinuation Phase:

  1. Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
  3. For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;
  4. If female, currently pregnant or breastfeeding or planning on conception;
  5. Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;
  6. Meets current DSM-5 criteria for any current alcohol use disorder;
  7. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
  8. Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);
  9. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
1,516 participants (actual)

Study arms

  • Experimental
    Retention: SL-BUP standard dose + MM

    Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: SL-BUP · Behavioral: MM

  • Experimental
    Retention: SL-BUP high dose + MM

    High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: SL-BUP · Behavioral: MM

  • Experimental
    Retention: XR-BUP + MM

    Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: XR-BUP · Behavioral: MM

  • Experimental
    Retention: XR-NTX + MM

    Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: XR-NTX · Behavioral: MM

  • Experimental
    Retention: SL-BUP standard dose + MMR

    Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: SL-BUP · Behavioral: MMR

  • Experimental
    Retention: SL-BUP high dose + MMR

    High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: SL-BUP · Behavioral: MMR

  • Experimental
    Retention: XR-BUP + MMR

    Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: XR-BUP · Behavioral: MMR

  • Experimental
    Retention: XR-NTX + MMR

    Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: XR-NTX · Behavioral: MMR

  • Experimental
    Discontinuation: Discontinue SL-BUP with SL-BUP + MM

    Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: SL-BUP · Behavioral: MM

  • Experimental
    Discontinuation: Discontinue SL-BUP with XR-BUP + MM

    Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: XR-BUP · Behavioral: MM

  • Experimental
    Discontinuation: Discontinue XR-BUP with XR-BUP + MM

    Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: XR-BUP · Behavioral: MM

  • Experimental
    Discontinuation: Discontinue XR-NTX with XR-NTX + MM

    Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

    Drug: XR-NTX · Behavioral: MM

  • Experimental
    Discontinuation: Discontinue SL-BUP with SL-BUP + MMD

    Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: SL-BUP · Behavioral: MMD

  • Experimental
    Discontinuation: Discontinue SL-BUP with XR-BUP + MMD

    Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: XR-BUP · Behavioral: MMD

  • Experimental
    Discontinuation: Discontinue XR-BUP with XR-BUP + MMD

    Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: XR-BUP · Behavioral: MMD

  • Experimental
    Discontinuation: Discontinue XR-NTX with XR-NTX + MMD

    Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

    Drug: XR-NTX · Behavioral: MMD

Interventions

  • DrugBuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daily dosing of sublingual buprenorphine-naloxone

    Also known as: sublingual buprenorphine, Suboxone

  • DrugCAM2038Studies of CAM2038CAM2038 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Weekly/monthly dosing of extended-release injectable buprenorphine

    Also known as: extended-release buprenorphine, CAM2038, Brixadi

  • DrugNaltrexoneStudies of NaltrexoneNaltrexone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Monthly dosing of extended-release injectable naltrexone

    Also known as: extended-release naltrexone, Vivitrol

  • BehavioralMM

    MM consists of standard Medical Management and the usual counseling at the treatment program.

  • BehavioralMMR

    MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

  • BehavioralMMD

    MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

06

What researchers measure

Primary outcomes

  1. Retention: Continuous retention in MOUD treatment through 26 weeks

    Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.

    Time frame: Retention: from randomization through week 26

  2. Discontinuation: Completed Discontinuation without Relapse

    Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.

    Time frame: Discontinuation: from randomization through week 24 follow up

Secondary outcomes

  1. Retention KS1: Weekly opioid abstinence

    Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.

    Time frame: Retention: from randomization through week 26

  2. Retention KS2: Treatment effectiveness

    Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.

    Time frame: Retention: at week 26

  3. Retention KS3: Treatment by baseline severity

    Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).

    Time frame: Retention: at week 26

  4. Discontinuation KS1: Completed Discontinuation

    Completed Discontinuation without regard to relapse status

    Time frame: Discontinuation: from randomization through week 24 follow up

  5. Discontinuation KS2: Relapse

    Relapse - separate binary outcome without regard to discontinuation status

    Time frame: Discontinuation: from randomization through week 24 follow up

  6. Discontinuation KS3: Safety

    Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.

    Time frame: Discontinuation: from randomization through week 24 follow up

  7. Discontinuation KS4: Treatment effectiveness

    Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).

    Time frame: Discontinuation: at end of taper (EoT) and week 24 follow up

07

Study locations

21 sites
  • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
    Little Rock, Arkansas 72205, United States
  • Tarzana Treatment Centers, Inc.
    Tarzana, California 91356, United States
  • Liberation Programs, Inc.
    Bridgeport, Connecticut 06610, United States
  • Operation PAR
    Clearwater, Florida 33760, United States
  • Gateway Community Services
    Jacksonville, Florida 32204, United States
  • Aspire Health Partners
    Orlando, Florida 32806, United States
  • Mountain Manor / Maryland Treatment Centers
    Baltimore, Maryland 21229, United States
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
  • Stanley Street Treatment and Resources, Inc.
    Fall River, Massachusetts 02720, United States
  • Square Medical Group, LLC
    Newton, Massachusetts 02458, United States
  • Gibson Center for Behavioral Change
    Cape Girardeau, Missouri 63703, United States
  • Dartmouth Hitchcock - ATP
    Lebanon, New Hampshire 03766, United States
  • University of New Mexico Addiction and Substance Abuse Program
    Albuquerque, New Mexico 87106, United States
  • Bellevue Hospital Center
    New York, New York 10016, United States
  • Adapt Integrated Health Care
    Roseburg, Oregon 97470, United States
  • Adapt Integrated Health Care
    Winston, Oregon 97496, United States
  • Center for Psychiatric and Chemical Dependency Services (CPCDS)
    Pittsburgh, Pennsylvania 15213, United States
  • Internal Medicine Recovery Engagement Program (IM-REP)
    Pittsburgh, Pennsylvania 15219, United States
  • Shoreline Behavioral Health Services
    Conway, South Carolina 29526, United States
  • Huntsman Mental Health Institute / University of Utah
    Salt Lake City, Utah 84108, United States
  • Chestnut Ridge Center
    Morgantown, West Virginia 26505, United States
08

References and documents

Publications

  • Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Weiss RD, Nunes EV. Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemp Clin Trials. 2025 Mar;150:107816. doi: 10.1016/j.cct.2025.107816. Epub 2025 Jan 20. PubMed 39842691 ↗
  • Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemp Clin Trials. 2024 Jul;142:107543. doi: 10.1016/j.cct.2024.107543. Epub 2024 Apr 23. PubMed 38657730 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy). Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/. The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Data sharing details ↗ · datashare.nida.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 66 months is above that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jul 9, 2020
StartActual
Jun 8, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04464980
Lead sponsor
NYU Langone Health
Collaborators
New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Responsible party
Sponsor
First posted
Jul 9, 2020
Start date
Jun 8, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Edward V Nunes, MD
principal investigator · New York State Psychiatric Institute/Columbia University Irving Medical Center
John Rotrosen, MD
principal investigator · NYU Langone Health
Roger Weiss, MD
principal investigator · Harvard Medical School/McLean Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Buprenorphine · CAM2038 · Naltrexone

Start the discussion